ArticleJournal of experimental & clinical cancer research : CR2016
MicroRNA-203 suppresses gastric cancer growth by targeting PIBF1/Akt signaling.
Article in Journal of experimental & clinical cancer research : CR, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- MicroRNA-203 restrains epithelial-mesenchymal transition, invasion and migration of papillary thyroid cancer by downregulating AKT3.Cell cycle (Georgetown, Tex.) · 2020Article
- Clinical significance of serum MicroRNA-203 in patients with acute myeloid leukemia.Bioengineered · 2019Article
- Diagnostic and prognostic significance of serum miR-203 in patients with acute myeloid leukemia.International journal of clinical and experimental pathology · 2019Article
- MiR-203 acts as a radiosensitizer of gastric cancer cells by directly targeting ZEB1.OncoTargets and therapy · 2019Article
- Identifying cancer-related microRNAs based on subpathways.IET systems biology · 2018Article
- Long non-coding RNA PTENP1 interacts with miR-193a-3p to suppress cell migration and invasion through the PTEN pathway in hepatocellular carcinoma.Oncotarget · 2017Article
- Retraction Note: MicroRNA-203 suppresses gastric cancer growth by targeting PIBF1/Akt signaling.Journal of experimental & clinical cancer research : CR · 2017Article
- microRNA-203 suppresses invasion of gastric cancer cells by targeting ERK1/2/Slug/ E-cadherin signaling.Cancer biomarkers : section A of Disease markers · 2017Article
- Linc00152 Functions as a Competing Endogenous RNA to Confer Oxaliplatin Resistance and Holds Prognostic Values in Colon Cancer.Molecular therapy : the journal of the American Society of Gene Therapy · 2016Article
- miR-489 acts as a tumor suppressor in human gastric cancer by targeting PROX1.American journal of cancer research · 2016Article
- Identification of HRAS as cancer-promoting gene in gastric carcinoma cell aggressiveness.American journal of cancer research · 2016Article
Corrections and comments
- Retraction · 2017-05-03Duplication of/in Image ·
- Retracted
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMicroRNAs (miRNAs) have been proved involved in many tumorigenic behaviors including tumor growth. But, the clinical significance and functions of miRNA-203 in gastric cancer (GC) remain elusive.
resultsDecreased expression of miRNA-203 was correlated with tumor size, poor prognosis and recurrence in GC patients. Overexpression of miR-203 or knockdown of its target progesterone immunomodulatory binding factor 1 (PIBF1) inhibited GC growth in vitro and in vivo, while miR-203 knockdown promoted GC proliferation. In addition, PIBF1 overexpression attenuated the inhibitory effects of miR-203 on GC growth and enhanced that effect on p-Akt expression.
conclusionsMiR-203 as a tumor biomarker suppresses GC growth through targeting the PIBF1/Akt signaling, suggesting that it may have the important therapeutic potential for the treatment of GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.